Norm construction of scores for patient reported outcomes of hypertension
-
摘要:
目的 构建高血压患者报告结局的划界常模,为社区快速判断高血压患者报告结局状态提供依据。 方法 2020年4—6月,随机抽取云南省2市4县中确诊且为单一用药的社区高血压患者,填写“高血压患者报告结局调查问卷”并计算“PROISCD-HY(V1.0)”量表得分,将人群作聚类分析后,以聚类结果作为人群划分依据,建立高血压患者报告结局得分的划界常模。 结果 此次调查最终收回487份单一用药的高血压患者报告结局调查问卷,经两步聚类法进行聚类分析,将调查对象按年龄和性别分为4类,即:男性≥65岁114例、18~64岁89例,女性≥65岁160例、18~64岁124例。4类人群除“精神/信仰”领域差异无统计学意义外,其余领域差异均有统计学意义(均P<0.05),聚类划分合理。以0.5s为间距,(x±s)和(x±0.5s)为界点构建高血压患者报告结局的划界常模,分为5种状态:[0, x-s)非常差,[x-s,x-0.5s)差,[x-0.5s,x+0.5s)一般,[x+0.5s,x+s)好,[x+s,100)非常好。最终量表总分的划界常模为:[0, 66.23),[66.23, 70.01),[70.01, 77.56),[77.56, 81.33),[81.33, 100)。其中,18~64岁男性量表总分划界常模为:[0, 70.08),[70.08, 73.50),[73.50, 80.34),[80.34, 83.76),[83.76, 100);18~64岁女性为:[0, 68.19),[68.19, 72.08),[72.08, 79.85),[79.85, 83.73),[83.73, 100);≥65岁男性量表总分划界常模为:[0, 65.73),[65.73, 69.43),[69.43, 76.81),[76.81, 80.51),[80.51, 100);≥65岁女性为:[0, 64.15),[64.15, 67.49),[67.49, 74.17),[74.17, 77.51),[77.51, 100)。 结论 此次研究构建了高血压患者报告结局得分划界常模,为后续的高血压患者报告研究提供了数据支持和评价的参考标准。 Abstract:Objective To establish the demarcation norm of the patient-reported outcomes of hypertension, and provide evidence for clinical treatment. Methods Patients with hypertension diagnosed in 4 counties of 2 cities in Yunnan Province who were single-drug patients were randomly selected from April to June 2020. The questionnaire of hypertension patient-reported outcomes was completed, and the scores of the scale (PROISCD-HY) were calculated. After clustering analysis of the population, the clustering results were used as the basis for population division to establish a cut-off norm for the reported outcome scores of hypertension patients. Results The survey eventually collected 487 single-drug hypertension patients reported outcome questionnaires. The two-step cluster method was used to cluster analysis, and the respondents were divided into 4 categories by age and gender: 114 males aged ≥65, 89 males aged 18-64, 160 females aged ≥65, and 124 females aged 18-64. In the 4 groups, there were all statistical differences in other fields except the field of "Spirit/Belief" (P < 0.05), and the clustering was reasonable. A demarcation norm for patients reported outcomes of hypertension was construct with intervals of 0.5s and boundary points of (x±s) and (x± 0.5s), and determined as 5 states: [0, x-s) very poor, [x-s, x-0.5s) poor, [x-0.5s, x+0.5s) average, [x+0.5s, x+s) good, [x+s, 100) very good. The demarcation norm for the final total scores of the scale were: [0, 66.23), [66.23, 70.01), [70.01, 77.56), [77.56, 81.33), [81.33, 100). Among them, the scores of demarcation norm of the 18-64-year-old male were: [0, 70.08), [70.08, 73.50), [73.50, 80.34), [80.34, 83.76), [83.76, 100); the 18-64-year-old female were: [0, 68.19), [68.19, 72.08), [72.08, 79.85), [79.85, 83.73), [83.73, 100); the norm of ≥65-year-old male were: [0, 65.73), [65.73, 69.43), [69.43, 76.81), [76.81, 80.51), [80.51, 100); ≥65-year-old female were: [0, 64.15), [64.15, 67.49), [67.49, 74.17), [74.17, 77.51), [77.51, 100). Conclusion This study constructs a demarcation norm for patient reported outcomes and provides data support and evaluation reference standard for related hypertension research. -
Key words:
- Hypertension /
- Patient reported outcomes /
- Demarcation Norm
-
表 1 487例高血压患者一般资料单因素方差分析(x±s,分)
Table 1. Univariate analysis of general data of 487 patients with hypertension (x±s, points)
变量 类别 例数 TOT 统计量 P值 年龄 18~64岁 213 76.36±7.39 6.953a <0.001 ≥65岁 274 71.78±7.06 性别 男性 203 74.78±7.83 2.486a 0.013 女性 284 73.07±7.60 民族 汉族 229 74.33±9.19 1.477a 0.141 其他 258 73.29±5.69 婚姻状况 未婚 6 73.53±6.74 0.602b 0.548 已婚 423 73.93±7.65 其他 58 72.77±6.93 文化程度 初中及以下 458 73.50±7.49 -3.353a 0.001 初中以上 29 78.30±7.12 注:TOT为量表总分。a为t值,b为F值。 表 2 最终聚类结果
Table 2. The final clustering results
组别 性别 年龄 例数[例(%)] 1 男性 ≥65岁 114(23.4) 2 女性 ≥65岁 160(32.9) 3 女性 18~64岁 124(25.5) 4 男性 18~64岁 89(18.3) 注:文化程度的重要性(0.23)<1.00,因此不纳入聚类分析。 表 3 4组高血压患者PRO得分的单因素方差分析(x±s,分)
Table 3. One-way ANOVA of PRO scores in four groups of hypertensive patients (x±s, points)
组别 例数 PHD MHD SHD SBD GMD SMD TOT 1 114 69.69±10.12 72.76±11.21 72.07±11.74 60.38±12.04 69.28±8.08 81.36±9.25 73.31±7.42 2 160 66.25±9.62 69.04±10.41 71.99±9.25 60.21±11.28 67.32±5.91 77.99±10.61 70.88±6.27 3 124 74.15±12.08 73.38±11.68 78.92±11.26 62.97±12.14 72.98±8.28 80.70±12.32 75.56±8.22 4 89 75.87±11.34 75.20±10.96 77.89±11.94 61.83±12.34 73.42±7.83 82.74±10.12 76.53±6.98 F值 20.469 6.994 14.303 1.577 19.675 4.340 15.407 P值 <0.001 <0.001 <0.001 0.194 <0.001 0.005 <0.001 注:PHD为身体健康,MHD为心理健康,SHD为社会健康,SBD为精神/信仰健康,GMD为共性模块,SMD为特异性模块,TOT为量表总分。 表 4 高血压患者PHD报告结局量表划界常模(分)
Table 4. The cut-off norm of PHD reported outcome Scale in hypertensive patients (points)
性别 年龄 非常差 差 一般 好 非常好 男性 18~64岁 [0, 65.15) [65.15, 70.78) [70.78, 82.03) [82.03, 87.65) [87.65, 100) ≥65岁 [0, 59.45) [59.45, 64.47) [64.47, 74.51) [74.51, 79.53) [79.53, 100) 合计 [0, 61.41) [61.41, 66.97) [66.97, 78.08) [78.08, 83.63) [83.63, 100) 女性 18~64岁 [0, 62.24) [62.24, 68.29) [68.29, 80.39) [80.39, 86.44) [86.44, 100) ≥65岁 [0, 56.73) [56.73, 61.64) [61.64, 71.44) [71.44, 76.35) [76.35, 100) 合计 [0, 58.43) [58.43, 64.19) [64.19, 75.71) [75.71, 81.47) [81.47, 100) 全人群 [0, 59.61) [59.61, 65.32) [65.32, 76.73) [76.73, 82.43) [82.43, 100) 注:PHD为身体健康。 表 5 高血压患者MHD报告结局量表划界常模(分)
Table 5. The cut-off norm of MHD reported outcome Scale in hypertensive patients (points)
性别 年龄 非常差 差 一般 好 非常好 男性 18~64岁 [0, 65.16) [65.16, 70.50) [70.50, 81.18) [81.18, 86.52) [86.52, 100) ≥65岁 [0, 61.05) [61.05, 66.70) [66.70, 77.99) [77.99, 83.63) [83.63, 100) 合计 [0, 62.74) [62.74, 68.31) [68.31, 79.45) [79.45, 85.02) [85.02, 100) 女性 18~64岁 [0, 62.43) [62.43, 68.13) [68.13, 79.52) [79.52, 85.21) [85.21, 100) ≥65岁 [0, 59.32) [59.32, 64.64) [64.64, 75.27) [75.27, 80.58) [80.58, 100) 合计 [0, 59.85) [59.85, 65.46) [65.46, 76.68) [76.68, 82.29) [82.29, 100) 全人群 [0, 60.98) [60.98, 66.61) [66.61, 77.87) [77.87, 83.50) [83.50, 100) 注:MHD为心理健康。 表 6 高血压患者SHD报告结局量表划界常模(分)
Table 6. The cut-off norm of SHD reported outcome Scale in hypertensive patients (points)
性别 年龄 非常差 差 一般 好 非常好 男性 18~64岁 [0, 66.34) [66.34, 72.29) [72.29, 84.18) [84.18, 90.12) [90.12, 100) ≥65岁 [0, 60.31) [60.31, 66.16) [66.16, 77.86) [77.86, 83.71) [83.71, 100) 合计 [0, 62.59) [62.59, 68.67) [68.67, 80.82) [80.82, 86.89) [86.89, 100) 女性 18~64岁 [0, 67.40) [67.40, 73.17) [73.17, 84.70) [84.70, 90.46) [90.46, 100) ≥65岁 [0, 63.13) [63.13, 67.76) [67.76, 77.01) [77.01, 81.63) [81.63, 100) 合计 [0, 64.45) [64.45, 69.85) [69.85, 80.64) [80.64, 86.03) [86.03, 100) 全人群 [0, 63.66) [63.66, 69.35) [69.35, 80.72) [80.72, 86.40) [86.40, 100) 注:SHD为社会健康。 表 7 高血压患者SBD报告结局量表划界常模(分)
Table 7. The cut-off norm of SBD reported outcome Scale in hypertensive patients (points)
性别 年龄 非常差 差 一般 好 非常好 男性 18~64岁 [0, 49.51) [49.51, 55.75) [55.75, 68.23) [68.23, 74.47) [74.47, 100) ≥65岁 [0, 48.39) [48.39, 54.35) [54.35, 66.27) [66.27, 72.23) [72.23, 100) 合计 [0, 48.87) [48.87, 54.96) [54.96, 67.13) [67.13, 73.21) [73.21, 100) 女性 18~64岁 [0, 50.51) [50.51, 56.68) [56.68, 69.01) [69.01, 75.17) [75.17, 100) ≥65岁 [0, 49.25) [49.25, 54.86) [54.86, 66.08) [66.08, 71.69) [71.69, 100) 合计 [0, 49.75) [49.75, 55.63) [55.63, 67.38) [67.37, 73.25) [73.25, 100) 全人群 [0, 49.39) [49.39, 55.35) [55.35, 67.27) [67.27, 73.23) [73.23, 100) 注:SBD为精神/信仰健康。 表 8 高血压患者GMD报告结局量表划界常模(分)
Table 8. The cut-off norm of GMD reported outcome Scale in hypertensive patients (points)
性别 年龄 非常差 差 一般 好 非常好 男性 18~64岁 [0, 66.22) [66.22, 70.04) [70.04, 77.68) [77.68, 81.5) [81.50, 100) ≥65岁 [0, 61.02) [61.02, 65.06) [65.06, 73.13) [73.13, 77.16) [77.16, 100) 合计 [0, 62.97) [62.97, 67.08) [67.08, 75.29) [75.29, 79.39) [79.39, 100) 女性 18~64岁 [0, 64.76) [64.76, 68.95) [68.95, 77.32) [77.32, 81.50) [81.50, 100) ≥65岁 [0, 61.51) [61.51, 64.52) [64.52, 70.54) [70.54, 73.55) [73.55, 100) 合计 [0, 62.32) [62.32, 66.15) [66.15, 73.80) [73.80, 77.62) [77.62, 100) 全人群 [0, 62.57) [62.57, 66.52) [66.52, 74.42) [74.42, 78.37) [78.37, 100) 注:GMD为共性模块。 表 9 高血压患者SMD报告结局量表划界常模(分)
Table 9. The cut-off norm of SMD reported outcome Scale in hypertensive patients (points)
性别 年龄 非常差 差 一般 好 非常好 男性 18~64岁 [0, 72.81) [72.81, 77.92) [77.92, 88.14) [88.14, 93.25) [93.25, 100) ≥65岁 [0, 72.03) [72.03, 76.61) [76.61, 85.76) [85.76, 90.33) [90.33, 100) 合计 [0, 72.34) [72.34, 77.17) [77.17, 86.83) [86.83, 91.66) [91.66, 100) 女性 18~64岁 [0, 71.37) [71.37, 76.50) [76.50, 86.76) [86.76, 91.89) [91.89, 100) ≥65岁 [0, 65.34) [65.34, 71.39) [71.39, 83.48) [83.48, 89.52) [89.52, 100) 合计 [0, 67.76) [67.76, 73.51) [73.51, 85.01) [85.01, 90.76) [90.76, 100) 全人群 [0, 69.55) [69.55, 74.98) [74.98, 85.83) [85.83, 91.25) [91.25, 100) 注:SMD为特异性模块。 表 10 高血压患者TOT报告结局量表划界常模(分)
Table 10. The cut-off norm of TOT reported outcome Scale in hypertensive patients (points)
性别 年龄 非常差 差 一般 好 非常好 男性 18~64岁 [0, 70.08) [70.08, 73.50) [73.50, 80.34) [80.34, 83.76) [83.76, 100) ≥65岁 [0, 65.73) [65.73, 69.43) [69.43, 76.81) [76.81, 80.51) [80.51, 100) 合计 [0, 67.40) [67.40, 71.09) [71.09, 78.47) [78.47, 82.16) [82.16, 100) 女性 18~64岁 [0, 68.19) [68.19, 72.08) [72.08, 79.85) [79.85, 83.73) [83.73, 100) ≥65岁 [0, 64.15) [64.15, 67.49) [67.49, 74.17) [74.17, 77.51) [77.51, 100) 合计 [0, 65.47) [65.47, 69.27) [69.27, 76.87) [76.87, 80.67) [80.67, 100) 全人群 [0, 66.23) [66.23, 70.01) [70.01, 77.56) [77.56, 81.33) [81.33, 100) 注:TOT为量表总分。 -
[1] 国家心血管病中心. 全国高血压日: 血压要知晓, 降压要达标[J]. 上海医药, 2021, 42(19): 14. https://www.cnki.com.cn/Article/CJFDTOTAL-MSZK202306033.htmNational Hypertension Day: know your blood pressure and meet your blood pressure standards[J]. Shanghai Medicine, 2021, 42(19): 14. https://www.cnki.com.cn/Article/CJFDTOTAL-MSZK202306033.htm [2] 彭丽霞, 张勇. 高血压患者报告结局的研究现状[J]. 保健医学研究与实践, 2021, 18(1): 100-104. https://www.cnki.com.cn/Article/CJFDTOTAL-GXBJ202101023.htmPENG L X, ZHANG Y. Research status of hypertensive patient-reported outcomes[J]. Health Medicine Research and Practice, 2021, 18(1): 100-104. https://www.cnki.com.cn/Article/CJFDTOTAL-GXBJ202101023.htm [3] HAN S Y, MO G J, GAO T J, et al. Age, sex, residence, and region-specific differences in prevalence and patterns of multimorbidity among older Chinese: evidence from Chinese Longitudinal Healthy Longevity Survey[J]. BMC Public Health, 2022, 22(1): 1116. doi: 10.1186/s12889-022-13506-0 [4] ROGGE A A, FISCHER F, OTTO L, et al. Assessment of patient-reported outcomes in routine medical care: patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs)[J]. Anasthesiol Intensivmed Notfallmed Schmerzther, 2022, 57(2): 150-155. doi: 10.1055/a-1452-2788 [5] QIAN Y R, WALTERS S J, JACQUES R, et al. Comprehensive review of statistical methods for analysing patient-reported outcomes (PROs) used as primary outcomes in randomised controlled trials (RCTs) published by the UK ' s Health Technology Assessment (HTA) journal (1997-2020)[J]. BMJ Open, 2021, 11(9): e051673. DOI: 10.1136/bmjopen-2021-051673. [6] 陈晴. 基于SCL-90的新生心理健康状况调查分析[J]. 产业与科技论坛, 2022, 21(9): 94-95. https://www.cnki.com.cn/Article/CJFDTOTAL-CYYT202209044.htmCHEN Q. Investigation and analysis of new students' mental health based on SCL-90[J]. Industry and Technology Forum, 2022, 21(9): 94-95. https://www.cnki.com.cn/Article/CJFDTOTAL-CYYT202209044.htm [7] 于媛, 李敏, 康然, 等. 食管癌患者加速康复术后生活质量水平及影响因素分析[J]. 中华肿瘤杂志, 2022, 44(4): 341-346.YU Y, LI M, KANG R, et al. Analysis of quality of life and influencing factors in patients with esophageal cancer after enhanced rehabilitation[J]. Chinese Journal of Oncology, 2022, 44(4): 341-346. [8] 吴文林, 李瑶, 鲁雁秋, 等. 患者报告结局在艾滋病临床领域的应用及研究进展[J]. 中国艾滋病性病, 2022, 28(5): 617-620. https://www.cnki.com.cn/Article/CJFDTOTAL-XBYA202205026.htmWU W L, LI Y, LU Y Q, et al. Application and research progress of patient-reported outcomes in the clinical field of HIV/AIDS[J]. CHINESE Journal of AIDS & STD, 2022, 28(5): 617-20. https://www.cnki.com.cn/Article/CJFDTOTAL-XBYA202205026.htm [9] 林沅锜, 许军, 储雪琴, 等. 广东省城镇老年人口自测健康评定量表常模的制定[J]. 广东医学, 2018, 39(11): 1708-1712. doi: 10.3969/j.issn.1001-9448.2018.11.028LIN Y Q, XU J, CHU X Q, et al. Development of the norm of the self-assessment health assessment scale for the urban elderly population in Guangdong Province[J]. Guangdong Medicine, 2018, 39(11): 1708-1712. doi: 10.3969/j.issn.1001-9448.2018.11.028 [10] WANG X S, GOTTUMUKKALA V. Patient-reported outcomes: is this the missing link in patient-centered perioperative care?[J]. Best Pract Res Clin Anaesthesiol, 2021, 35(4): 565-573. doi: 10.1016/j.bpa.2020.10.006 [11] 唐顺定, 万崇华, 宋莹, 等. 高血压患者报告的临床结局测定量表的应用考评[J]. 昆明医科大学学报, 2022, 43(3): 60-66. https://www.cnki.com.cn/Article/CJFDTOTAL-KMYX202203011.htmTANG S D, WAN C H, SONG Y, et al. Application evaluation of clinical outcome measurement scales reported by patients with hypertension[J]. Journal of Kunming Medical University, 2022, 43(3): 60-66. https://www.cnki.com.cn/Article/CJFDTOTAL-KMYX202203011.htm [12] 沈美萍, 楼晓芳, 陈朔晖, 等. 儿科中心静脉导管相关性血栓发生的临床特征聚类分析[J]. 护理与康复, 2019, 18(10): 23-26. https://www.cnki.com.cn/Article/CJFDTOTAL-HLKF201910007.htmSHEN M P, LOU X F, CHEN S H, et al. Cluster analysis of clinical features of thrombosis associated with venous catheters in pediatric centers[J]. Nursing and Rehabilitation, 2019, 18(10): 23-26. https://www.cnki.com.cn/Article/CJFDTOTAL-HLKF201910007.htm [13] 薛允莲. 中国城镇居民亚健康评定量表的常模制定及亚健康状态影响因素模型的构建研究[D]. 广州: 南方医科大学, 2020.XUE Y L. The norm formulation of the sub-health assessment scale for Chinese urban residents and the construction of the influencing factor model of sub-health status[D]. Guangzhou: Southern Medical University, 2020. [14] 王爱梅, 章新琼, 王婷婷, 等. 肺癌患者运动自我效能量表安徽省常模的构建[J]. 中国全科医学, 2022, 25(13): 1603-1611. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202213009.htmWANG A M, ZHANG X Q, WANG T T, et al. Establishment of the norms of exercise self-efficacy scale for lung cancer patients in Anhui province[J]. Chinese General Practice, 2022, 25(13): 1603-1611. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202213009.htm [15] 冯叶芳, 张仲, 吴伟旋, 等. 哈尔滨市城镇居民亚健康评定量表的常模研制[J]. 中国全科医学, 2021, 24(10): 1260-1265. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202110015.htmFENG Y F, ZHANG Z, WU W X, et al. Establishment of the norms of sub-health measurement scale version 1.0 for Harbin urban residents[J]. Chinese General Practice, 2021, 24(10): 1260-1265. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202110015.htm [16] 王永馨. 社区老年高血压患者降压药物使用现状及依从性分析[D]. 石河子: 石河子大学, 2020.WANG Y X. Status and compliance of antihypertensive drugs in elderly patients with hypertension in community[D]. Shihezi: Shihezi University, 2020. [17] 惠娟. 联合用药与单一用药在高血压治疗中的有效性对比[J]. 医学食疗与健康, 2022, 20(3): 87-89, 96. https://www.cnki.com.cn/Article/CJFDTOTAL-YXSL202203026.htmHUI J. Comparison of the effectiveness of combined medication and single medication in the treatment of hypertension[J]. Medical Diet and Health, 2022, 20(3): 87-89, 96. https://www.cnki.com.cn/Article/CJFDTOTAL-YXSL202203026.htm [18] 竺琼, 陈春凤. 体质辨识在社区高血压管理中的应用[J]. 中华全科医学, 2022, 20(5): 836-838, 871. doi: 10.16766/j.cnki.issn.1674-4152.002467ZHU Q, CHEN C F. Application of constitution identification in community hypertension management[J]. Chinese Journal of General Practice, 2022, 20(5): 836-838, 871. doi: 10.16766/j.cnki.issn.1674-4152.002467 [19] WANG Y J, CHEN T, GAN W, et al. Association among high blood pressure health literacy, social support and health-related quality of life among a community population with hypertension: a community-based cross-sectional study in China[J]. BMJ Open, 2022, 12(6): e057495. DOI: 10.1136/bmjopen-2021-057495. [20] 黄文博, 冯娴, 姚元龙, 等. 全科医学视角下我国高血压患者的自我管理[J]. 中华全科医学, 2022, 20(7): 1085-1088. doi: 10.16766/j.cnki.issn.1674-4152.002529HUANG W B, FENG X, YAO Y L, et al. Self-management of hypertensive patients in China from the perspective of general practice[J]. Chinese Journal of General Practice, 2022, 20(7): 1085-1088. doi: 10.16766/j.cnki.issn.1674-4152.002529 -

计量
- 文章访问数: 297
- HTML全文浏览量: 99
- PDF下载量: 8
- 被引次数: 0